Cargando…
Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study
BACKGROUND: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. METHODS AND FINDINGS: In case-control and case-series...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046139/ https://www.ncbi.nlm.nih.gov/pubmed/21386992 http://dx.doi.org/10.1371/journal.pone.0017251 |
_version_ | 1782198928422207488 |
---|---|
author | Yao, Song Sucheston, Lara E. Millen, Amy E. Johnson, Candace S. Trump, Donald L. Nesline, Mary K. Davis, Warren Hong, Chi-Chen McCann, Susan E. Hwang, Helena Kulkarni, Swati Edge, Stephen B. O'Connor, Tracey L. Ambrosone, Christine B. |
author_facet | Yao, Song Sucheston, Lara E. Millen, Amy E. Johnson, Candace S. Trump, Donald L. Nesline, Mary K. Davis, Warren Hong, Chi-Chen McCann, Susan E. Hwang, Helena Kulkarni, Swati Edge, Stephen B. O'Connor, Tracey L. Ambrosone, Christine B. |
author_sort | Yao, Song |
collection | PubMed |
description | BACKGROUND: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. METHODS AND FINDINGS: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95% CI = 0.08–0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR = 0.36, 95% CI = 0.22–0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. CONCLUSION: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women. |
format | Text |
id | pubmed-3046139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30461392011-03-08 Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study Yao, Song Sucheston, Lara E. Millen, Amy E. Johnson, Candace S. Trump, Donald L. Nesline, Mary K. Davis, Warren Hong, Chi-Chen McCann, Susan E. Hwang, Helena Kulkarni, Swati Edge, Stephen B. O'Connor, Tracey L. Ambrosone, Christine B. PLoS One Research Article BACKGROUND: Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity. METHODS AND FINDINGS: In case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamin D (25OHD) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (ER), and molecular subtypes defined by ER, progesterone receptor (PR) and HER2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the Roswell Park Cancer Institute from 2003 to 2008. We found that breast cancer cases had significantly lower 25OHD concentrations than controls (adjusted mean, 22.8 versus 26.2 ng/mL, p<0.001). Among premenopausal women, 25OHD concentrations were lower in those with high- versus low-grade tumors, and ER negative versus ER positive tumors (p≤0.03). Levels were lowest among women with triple-negative cancer (17.5 ng/mL), significantly different from those with luminal A cancer (24.5 ng/mL, p = 0.002). In case-control analyses, premenopausal women with 25OHD concentrations above the median had significantly lower odds of having triple-negative cancer (OR = 0.21, 95% CI = 0.08–0.53) than those with levels below the median; and every 10 ng/mL increase in serum 25OHD concentrations was associated with a 64% lower odds of having triple-negative cancer (OR = 0.36, 95% CI = 0.22–0.56). The differential associations by tumor subtypes among premenopausal women were confirmed in case-series analyses. CONCLUSION: In our analyses, higher serum levels of 25OHD were associated with reduced risk of breast cancer, with associations strongest for high grade, ER negative or triple negative cancers in premenopausal women. With further confirmation in large prospective studies, these findings could warrant vitamin D supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women. Public Library of Science 2011-02-28 /pmc/articles/PMC3046139/ /pubmed/21386992 http://dx.doi.org/10.1371/journal.pone.0017251 Text en Yao et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Yao, Song Sucheston, Lara E. Millen, Amy E. Johnson, Candace S. Trump, Donald L. Nesline, Mary K. Davis, Warren Hong, Chi-Chen McCann, Susan E. Hwang, Helena Kulkarni, Swati Edge, Stephen B. O'Connor, Tracey L. Ambrosone, Christine B. Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title | Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title_full | Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title_fullStr | Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title_full_unstemmed | Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title_short | Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study |
title_sort | pretreatment serum concentrations of 25-hydroxyvitamin d and breast cancer prognostic characteristics: a case-control and a case-series study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046139/ https://www.ncbi.nlm.nih.gov/pubmed/21386992 http://dx.doi.org/10.1371/journal.pone.0017251 |
work_keys_str_mv | AT yaosong pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT suchestonlarae pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT millenamye pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT johnsoncandaces pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT trumpdonaldl pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT neslinemaryk pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT daviswarren pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT hongchichen pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT mccannsusane pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT hwanghelena pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT kulkarniswati pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT edgestephenb pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT oconnortraceyl pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy AT ambrosonechristineb pretreatmentserumconcentrationsof25hydroxyvitamindandbreastcancerprognosticcharacteristicsacasecontrolandacaseseriesstudy |